BioNTech SE (NASDAQ:BNTX) is one of the Stocks That Will Go To The Moon in 2026. On December 18, BioNTech SE announced the closing of its acquisition of CureVac N.V. (NASDAQ:CVAC), which is another mRNA-focused biotech firm from Mainz, Germany.
Management noted that the deal had closed after the expiration of the subsequent offering period in exchange for CureVac’s shares. As a result, the company now holds a majority stake in CureVac. This enables the company to integrate CureVac’s pipeline for oncology and infectious diseases.
In another update, on December 11, H.C. Wainwright reiterated a Buy rating on BioNTech SE with a $140 price target.
The bullish sentiment is based on the interim data from a Phase 2 trial testing Pumitamig (BNT327/BMS-986545), which is a bispecific antibody that targets both PD-L1 and VEGF-A. The treatment is being tested for patients with triple-negative breast cancer (TNBC). The results showed strong anti-tumor activity and tolerable safety. Management noted that the results support advancing to a Phase 3 trial called ROSETTA-BREAST-01.
H.C. Wainwright noted that the trial showed an impressive 72% overall response rate along with 62% confirmed ORR in first-line and second-line TNBC patients. The firm added that these impressive results derisk the ongoing phase 3 trials, suggesting the strong potential of Pumitamig plus chemotherapy becoming a treatment for first-line TNBC patients with PD-L1 expression.
BioNTech SE is a German biotechnology company that develops and commercializes novel immunotherapies and vaccines for cancer and infectious diseases. It is widely recognized for creating the first approved mRNA-based drug, the Pfizer-BioNTech COVID-19 vaccine, sold under the brand name Comirnaty.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.